Lyve-1 deficiency enhances the hepatic immune microenvironment entailing altered susceptibility to melanoma liver metastasis.

Immune microenvironment Liver Liver homeostasis Liver metastasis Lyve-1

Journal

Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795

Informations de publication

Date de publication:
10 Dec 2022
Historique:
received: 31 08 2022
accepted: 21 11 2022
entrez: 10 12 2022
pubmed: 11 12 2022
medline: 11 12 2022
Statut: epublish

Résumé

Hyaluronan receptor LYVE-1 is expressed by liver sinusoidal endothelial cells (LSEC), lymphatic endothelial cells and specialized macrophages. Besides binding to hyaluronan, LYVE-1 can mediate adhesion of leukocytes and cancer cells to endothelial cells. Here, we assessed the impact of LYVE-1 on physiological liver functions and metastasis. Mice with deficiency of Lyve-1 (Lyve-1-KO) were analyzed using histology, immunofluorescence, microarray analysis, plasma proteomics and flow cytometry. Liver metastasis was studied by intrasplenic/intravenous injection of melanoma (B16F10 luc2, WT31) or colorectal carcinoma (MC38). Hepatic architecture, liver size, endothelial differentiation and angiocrine functions were unaltered in Lyve-1-KO. Hyaluronan plasma levels were significantly increased in Lyve-1-KO. Besides, plasma proteomics revealed increased carbonic anhydrase-2 and decreased FXIIIA. Furthermore, gene expression analysis of LSEC indicated regulation of immunological pathways. Therefore, liver metastasis of highly and weakly immunogenic tumors, i.e. melanoma and colorectal carcinoma (CRC), was analyzed. Hepatic metastasis of B16F10 luc2 and WT31 melanoma cells, but not MC38 CRC cells, was significantly reduced in Lyve-1-KO mice. In vivo retention assays with B16F10 luc2 cells were unaltered between Lyve-1-KO and control mice. However, in tumor-free Lyve-1-KO livers numbers of hepatic CD4 Lyve-1 deficiency controlled hepatic metastasis in a tumor cell-specific manner leading to reduced growth of hepatic metastases of melanoma, but not CRC. Anti-tumorigenic effects are likely due to enhancement of the premetastatic hepatic immune microenvironment influencing early liver metastasis formation.

Sections du résumé

BACKGROUND BACKGROUND
Hyaluronan receptor LYVE-1 is expressed by liver sinusoidal endothelial cells (LSEC), lymphatic endothelial cells and specialized macrophages. Besides binding to hyaluronan, LYVE-1 can mediate adhesion of leukocytes and cancer cells to endothelial cells. Here, we assessed the impact of LYVE-1 on physiological liver functions and metastasis.
METHODS METHODS
Mice with deficiency of Lyve-1 (Lyve-1-KO) were analyzed using histology, immunofluorescence, microarray analysis, plasma proteomics and flow cytometry. Liver metastasis was studied by intrasplenic/intravenous injection of melanoma (B16F10 luc2, WT31) or colorectal carcinoma (MC38).
RESULTS RESULTS
Hepatic architecture, liver size, endothelial differentiation and angiocrine functions were unaltered in Lyve-1-KO. Hyaluronan plasma levels were significantly increased in Lyve-1-KO. Besides, plasma proteomics revealed increased carbonic anhydrase-2 and decreased FXIIIA. Furthermore, gene expression analysis of LSEC indicated regulation of immunological pathways. Therefore, liver metastasis of highly and weakly immunogenic tumors, i.e. melanoma and colorectal carcinoma (CRC), was analyzed. Hepatic metastasis of B16F10 luc2 and WT31 melanoma cells, but not MC38 CRC cells, was significantly reduced in Lyve-1-KO mice. In vivo retention assays with B16F10 luc2 cells were unaltered between Lyve-1-KO and control mice. However, in tumor-free Lyve-1-KO livers numbers of hepatic CD4
CONCLUSION CONCLUSIONS
Lyve-1 deficiency controlled hepatic metastasis in a tumor cell-specific manner leading to reduced growth of hepatic metastases of melanoma, but not CRC. Anti-tumorigenic effects are likely due to enhancement of the premetastatic hepatic immune microenvironment influencing early liver metastasis formation.

Identifiants

pubmed: 36496412
doi: 10.1186/s12935-022-02800-x
pii: 10.1186/s12935-022-02800-x
pmc: PMC9741792
doi:

Types de publication

Journal Article

Langues

eng

Pagination

398

Subventions

Organisme : Deutsche Stiftung Dermatologie e.V. (Deutsche Dermatologische Gesellschaft e.V. (DDG)/Arbeitsgemeinschaft Dermatologische Forschung e.V. (ADF)), Germany
ID : Clinician Scientist Program
Organisme : Deutsche Forschungsgemeinschaft
ID : SPP1937 (CE 140-2.2)
Organisme : Deutsche Forschungsgemeinschaft
ID : SPP1937 (CE 140-2.2)
Organisme : Deutsche Forschungsgemeinschaft
ID : 394046768
Organisme : Deutsche Forschungsgemeinschaft
ID : 394046768
Organisme : Deutsche Forschungsgemeinschaft
ID : 394046768

Informations de copyright

© 2022. The Author(s).

Références

Immunity. 2016 Mar 15;44(3):492-504
pubmed: 26982356
Am J Physiol Gastrointest Liver Physiol. 2016 Aug 1;311(2):G246-51
pubmed: 27288423
Dev Dyn. 2008 Jul;237(7):1901-9
pubmed: 18570254
Cancer Sci. 2018 Oct;109(10):3171-3182
pubmed: 30058195
J Clin Invest. 2017 Mar 1;127(3):1099-1114
pubmed: 28218627
Gut. 2013 Aug;62(8):1169-78
pubmed: 22637699
Nat Med. 2016 Aug;22(8):945-51
pubmed: 27428900
J Hepatol. 2021 Feb;74(2):380-393
pubmed: 32916216
Hepatology. 2018 Aug;68(2):707-722
pubmed: 29059455
JAMA Oncol. 2018 Oct 1;4(10):1382-1388
pubmed: 30073321
Ann Surg Oncol. 2009 Sep;16(9):2524-30
pubmed: 19568816
iScience. 2021 Jan 05;24(2):102032
pubmed: 33521599
FEBS Lett. 2006 Nov 13;580(26):6259-68
pubmed: 17070806
Cancer Res. 2002 Oct 1;62(19):5393-8
pubmed: 12359742
Nat Rev Gastroenterol Hepatol. 2018 Sep;15(9):555-567
pubmed: 29844586
Front Immunol. 2017 Nov 08;8:1479
pubmed: 29167669
Cancer Res. 2001 Nov 15;61(22):8079-84
pubmed: 11719431
Nat Immunol. 2017 Jul;18(7):762-770
pubmed: 28504698
Blood. 2017 Jan 26;129(4):405-414
pubmed: 27864295
Hepatology. 2010 Jun;51(6):2172-82
pubmed: 20513002
Am J Pathol. 2020 Feb;190(2):358-371
pubmed: 31783007
Blood. 2012 Aug 30;120(9):1899-907
pubmed: 22797697
J Pathol. 2006 May;209(1):67-77
pubmed: 16482496
J Clin Invest. 2011 Mar;121(3):985-97
pubmed: 21317534
Blood. 2017 Jan 26;129(4):415-419
pubmed: 27903529
Angiogenesis. 2021 May;24(2):289-310
pubmed: 33745018
Clin Cancer Res. 2016 Dec 15;22(24):5971-5982
pubmed: 27797969
J Biol Chem. 2001 Jun 1;276(22):19420-30
pubmed: 11278811
Nat Commun. 2011 Nov 22;2:555
pubmed: 22109529
Oncol Lett. 2017 Oct;14(4):3883-3892
pubmed: 28943897
Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4263-8
pubmed: 22371575
J Cell Biol. 1999 Feb 22;144(4):789-801
pubmed: 10037799
J Clin Invest. 2011 Feb;121(2):703-14
pubmed: 21293057
Nat Med. 2021 Jan;27(1):152-164
pubmed: 33398162
Biomed Res. 2014;35(1):37-45
pubmed: 24573200
Nat Nanotechnol. 2016 Nov;11(11):986-994
pubmed: 27668795
Melanoma Res. 2017 Aug;27(4):300-308
pubmed: 28445180
Blood. 2011 Aug 18;118(7):1912-22
pubmed: 21705499
Cancer Res. 2019 Feb 1;79(3):598-610
pubmed: 30530502
Science. 2017 Aug 25;357(6353):
pubmed: 28775214
Mol Cell Biol. 2007 Jan;27(2):595-604
pubmed: 17101772
Nature. 2010 Nov 11;468(7321):310-5
pubmed: 21068842
Cancer Res. 2017 Jul 1;77(13):3431-3441
pubmed: 28536280
J Cell Physiol. 2009 May;219(2):430-7
pubmed: 19170073
Matrix Biol. 2019 May;78-79:219-235
pubmed: 29425695
Biomed Res. 2016;37(3):187-98
pubmed: 27356606
J Transl Med. 2022 Feb 2;20(1):62
pubmed: 35109875
Gene. 2021 Feb 5;768:145284
pubmed: 33130055
Front Oncol. 2021 Jun 02;11:672660
pubmed: 34150638
PLoS One. 2013 May 22;8(5):e63463
pubmed: 23717428

Auteurs

Anna Sophia Jauch (AS)

Section of Clinical and Molecular Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Sebastian A Wohlfeil (SA)

Department of Dermatology, Venereology, and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, and Center of Excellence in Dermatology, 68135, Mannheim, Germany.
Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Céline Weller (C)

Section of Clinical and Molecular Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Bianca Dietsch (B)

Section of Clinical and Molecular Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Verena Häfele (V)

Section of Clinical and Molecular Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Ana Stojanovic (A)

Department of Immunobiochemistry, Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Maximilian Kittel (M)

Institute for Clinical Chemistry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Hendrik Nolte (H)

Max-Planck-Institute for Biology of Ageing, Cologne, Germany.

Adelheid Cerwenka (A)

Department of Immunobiochemistry, Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Michael Neumaier (M)

Institute for Clinical Chemistry, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Kai Schledzewski (K)

Department of Dermatology, Venereology, and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, and Center of Excellence in Dermatology, 68135, Mannheim, Germany.

Carsten Sticht (C)

NGS Core Facility, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Philipp-Sebastian Reiners-Koch (PS)

Department of Dermatology, Venereology, and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, and Center of Excellence in Dermatology, 68135, Mannheim, Germany.
European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Sergij Goerdt (S)

Department of Dermatology, Venereology, and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, and Center of Excellence in Dermatology, 68135, Mannheim, Germany.
European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Cyrill Géraud (C)

Section of Clinical and Molecular Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. cyrill.geraud@umm.de.
Department of Dermatology, Venereology, and Allergology, University Medical Center and Medical Faculty Mannheim, Heidelberg University, and Center of Excellence in Dermatology, 68135, Mannheim, Germany. cyrill.geraud@umm.de.
European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. cyrill.geraud@umm.de.

Classifications MeSH